longbridge
  • Explore
    Products
    Private Wealth ManagementUS StocksSG StocksHK StocksUS OptionsUS Pre-Market OptionsETFsREITsWarrantsCash Plus
    Tools
    Longbridge SkillLongbridge AILongbridge APIPaper TradingDividend HubLongbridge Pro
  • Café
longbridge

ABBISKO-B

2256

6.3001.87% ( -0.120 )
Delay Closed: Nov 17, 16:08:15
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile

News

  • Insider Buys Additional CN¥967k In Abbisko Medicine Stock

    Simplywall·Nov 16, 2026 at 12:18 AM
    02256-1.87%
  • Abbisko falls 6% in Hong Kong trading

    Market Movers·Nov 13, 2026 at 06:12 AM
    02256-1.87%
  • Abbisko climbs 6% as FDA approves pimicotinib

    Market Movers·Nov 12, 2026 at 05:15 AM
    02256-1.87%
  • Abbisko Medicine CEO Xu Yao-Chang Raises Stake to 11.26%

    PUBT·Nov 11, 2026 at 10:50 AM
    02256-1.87%
  • PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT

    PR Newswire·Nov 11, 2026 at 04:05 AM
    MKKGY+0.92%02256-1.87%
  • ABBISKO-B fell by approximately 6%

    Market Movers·Nov 6, 2026 at 01:32 AM
    02256-1.87%
  • Abbisko climbs 6%

    Market Movers·Nov 4, 2026 at 05:37 AM
    02256-1.87%
  • Abbisko Cayman Files HKEX Next Day Disclosure Return Announcing Share Buyback

    PUBT·Oct 29, 2026 at 01:28 PM
    02256-1.87%
  • Abbisko hits 52-week low

    Market Movers·Oct 29, 2026 at 01:41 AM
    02256-1.87%
LongbridgeAI
© 2026 Longbridge|Terms of ServicePrivacy Policy